Viking Therapeutics NASDAQ: VKTX is preparing for a potential 2029 launch of its obesity drug candidate VK2735 while studying whether patients can maintain weight loss with less frequent injections or a daily oral tablet, CEO Brian Lian said at the Jefferies Global Healthcare Conference in London.








